復宏漢霖(02696.HK)訂立星浩澎博技術服務協議
格隆匯3月28日丨復宏漢霖(02696.HK)發佈公吿,復星醫藥產業正在向復星醫藥全資附屬公司星浩澎博授出抗體藥物FS2101的授權。鑑於有關授權以及為確保就FS2101提供無縫服務,於2022年3月28日,公司與星浩澎博訂立星浩澎博技術服務協議,據此,公司同意就抗體藥物FS2101向星浩澎博提供額外CMC及臨牀前生物分析技術服務。
FS2101採用雞尾酒療法,中和活性覆蓋目前發現的主要新冠病毒變異株,用於新型冠狀病毒肺炎(COVID-19)暴露後預防或治療。基於星浩澎博技術服務協議,星浩澎博應向公司支付的代價總額為人民幣3527萬元。
鑑於公司可以承接從工藝開發到動態藥品生產管理規範(cGMP)生產的完整CMC技術服務、分析檢測服務、臨牀前毒理學研究及生物分析服務工作,本次與星浩澎博進行技術服務的合作,將有助於為集團創造商業利益,故董事認為訂立星浩澎博技術服務協議乃對公司有益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.